User Meeting 2016

Session

Concurrent Session 4: Radiotherapy II

25 Nov 2016, 13:30

National Centre for Synchrotron Science

Conveners

Concurrent Session 4: Radiotherapy II

• Jean-François Adam (Université Grenoble-Alpes & Centre Hospitalier Universitaire Grenoble-Alpes)

218. Curing Cancer with the Synchrotron

Prof. Peter Rogers (University of melbourne)

25/11/2016, 13:30

Radiotherapy

Oral

Microbeam radiotherapy (MRT) was proposed as a novel RT paradigm for treating cancer some time ago. However, progress has been slow and it is unclear when or if human cancers will be treated with synchrotron radiation. There are numerous biological, medical, technical, regulatory and ethical issues to consider before a human is subjected to synchrotron MRT. This talk will give an overview of...

191. A pre-clinical sample positioning system for microbeam radiotherapy at the Australian Synchrotron

Mr Micah Barnes (RMIT)

25/11/2016, 14:00

Radiotherapy

Oral

Microbeam radiation therapy (MRT), using X-rays from a synchrotron, is a novel, preclinical form of radiotherapy that shows promise of providing a major advance in cancer control if successfully translated to clinical practice (Brauer-Krisch et al, 2010; Crosbie et al, 2010). Clinical translation of MRT requires developing a protocol for a patient positioning system (PPS). Following recent...

209. Microbeam Dosimetric Verification using Presage® Dosimeters

Mr Frank Gagliardi (William Buckland Radiotherapy Centre)

25/11/2016, 14:15

Radiotherapy

Oral

Dosimetric properties of synchrotron microbeams are extremely difficult to measure due to the small field sizes employed (typically 50 um width with 200 – 400 um peak-to-peak spacing) and must undergo rigorous validation before patient treatments can be performed on the IMBL. The radiochromic PRESAGE® dosimeter offers a unique opportunity to validate dosimetry models in 3D with similar...

186. How big is that diamond?

Dr Duncan Butler (ARPANSA)

25/11/2016, 14:30

Radiotherapy

Oral

Detectors using diamond for the active layer are becoming more popular in radiotherapy because they have a relatively flat energy response and can be small. Recently published modelling of a new solid-state diamond detector (PTW model 60019) suggests that only a region of diameter 0.6 mm responds to radiation. The manufacturer’s specifications indicate that the active area is a disk of...

261. Progress report on the European MRT program: What can the Australian MRT community learn from the European experience?

Dr Jayde Livingstone (Australian Synchrotron)

25/11/2016, 14:45

Radiotherapy

Oral

There are currently two biomedical synchrotron beamlines in the world with an MRT program and an active MRT user base: ID17 at the European Synchrotron Radiation Facility (ESRF), France, and the Australian Synchrotron’s Imaging and Medical Beamline (IMBL). The European program has been ongoing since the 1990s and has identified radioresistant brain tumours as a clinical target for MRT. Indeed,...

263. Treatment planning for synchrotron microbeam radiotherapy

Mr Liam Day (Royal Melbourne Institute of Technology)

25/11/2016, 15:00

Radiotherapy

Oral

**Introduction** Synchrotron microbeam radiation therapy (MRT) is a novel radiotherapy modality with significant clinical potential. We have produced a simple dose calculation algorithm for MRT using the Eclipse Treatment Planning System (TPS), by Varian Medical Systems. **Method** The calculation engine in Eclipse was configured to directly evaluate ‘peak’ doses. Monte...